Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The core platform technology comprises proprietary targeted lipid nanoparticles (tLNP) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. The platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com. 

Vida Ventures

Leaps by Bayer

Bristol-Myers Squibb

Alexandria Venture Investments

Eli Lilly & Company Foundation

Novartis Venture Fund

OrbiMed

Pfizer Venture Investments

Polaris Partners

RA Capital Management

Capstan Therapeutics

This week Capstan CSO and EVP of R&D, Adrian Bot, M.D., Ph.D., will participate in a fireside chat at the 2nd Annual H.C. Wainwright & Co., LLC Cell Therapy Virtual Conference, where he will discuss our mission to multiply the possibilities for patients through our targeted in vivo RNA-based approach.

It’s an exciting time to be on Team Capstan as we look to advance our in vivo CAR-T lead program, CPTX2309, using the proceeds of our recently announced oversubscribed Series B financing: https://lnkd.in/eN5WcfkX
 
We are hiring at multiple levels across various disciplines including in vitro pharmacology, analytical development, formulation & process development, and more.
 
Interested in joining our creative, collaborative team committed to pioneering a new frontier of medicine? Read more about our open positions and apply here: https://lnkd.in/eiU8hT7y 

Today we announced the successful closing of an oversubscribed Series B financing of $175 million, which will support the advancement of our lead program, CPTX2309, through clinical proof-of-concept studies for #autoimmune disorders. We are also pleased to welcome Nanna Lüneborg, Ph.D., MBA, to our Board of Directors.
 
CPTX2309 is the flagship of our tLNP platform, delivering an mRNA payload encoding for an anti-CD19 chimeric antigen receptor to CD8-expressing T cells, effectively engineering CAR-T cells in vivo for the treatment of autoimmune disorders.
 
We thank each of our investors for believing in and supporting our mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA-based therapies.

Read more in our press release: https://lnkd.in/eN5WcfkX

Forbion, Johnson & Johnson Innovation JJDC Inc, Mubadala, Perceptive Advisors, Sofinnova Investments 

A sincere congratulations is in order for our very own President and Chief Executive Officer, Dr. Laura Shawver, who was recently recognized as the 2024 Duane Roth Endowed Award Lecture recipient for her contributions in the oncology space.
 
Dr. Shawver’s work as a scientist, leader, patient and patient advocate spans across decades and has led to new paradigms in cancer research and support for patients.
 
She has touched the lives of so many and we are thankful to have her as the leader of Team Capstan. Read more about Dr. Shawver and the Duane Roth Award here: https://lnkd.in/gMfgjRXc

Happy #InternationalWomensDay! We are thankful for the committed, collaborative and creative women on Team Capstan who drive forward our mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA-based therapies. #IWD2024 

Capstan Therapeutics is a biotechnology company that collects and processes personal information from various sources, including directly from individuals, third parties, and automatically through cookies. The company uses this information for various purposes, such as providing information, responding to inquiries, and improving website functionality.

COM:CAPSTANTX

Capstan Therapeutics

Filings Not Available